COVID-19: Potential neutralizing antibody against SARS-CoV-2 found in a SARS patient
Researchers have found a monoclonal antibody in the blood of a SARS patient that has potent therapeutic action against SARS-CoV-2 (COVID-19 causing virus).
On May 18, an American biotech company, Vir Biotechnology, announced in a press release that their researchers have found a monoclonal antibody (MAb), S309, in the blood of a SARS (severe acute respiratory syndrome) patient that has potent therapeutic action against SARS-CoV-2 ( COVID-19 causing virus) and other viruses from the coronavirus family.
The antibody reportedly has strong neutralising action and effector functions (recruits other cells of the immune system to kill the virus-infected cell) against the SARS-CoV-2 virus.
Monoclonal antibodies are those that are made from a single parent and act against unique sites on antigens (foreign substances against which our body mounts an immune response).
The findings of the study have already been published in the peer-reviewed journal Nature.
According to the study, researchers had earlier recognised the presence of a set of antibodies in a person who had SARS in 2003. These antibodies cross-reacted with animal SARS virus too. Now, the scientists checked the cross-reactivity of specific monoclonal antibodies from memory B cells isolated from the same patient in 2013. The study describes 19 mAbs from the 2004 sample and six mAbs from the 2014 sample. These antibodies bound to various sites in both SARS-CoV-1 (SARS-causing virus) and SARS-CoV-2 virus. Though some MAbs showed weak neutralising action, in particular, MAb309 showed potent neutralizing action against both viruses. The antibody bound to a highly conserved protein/glycan epitope (part of an antigen over which an antibody binds) on the spike protein of the virus. Spike protein is what the SARS-CoV-2 virus uses to gain entry into healthy cells.
The binding site for MAb309 is different from the receptor-binding domain (the part that binds to the ACE2 receptors on healthy cells). In other words, it does not compete with viral binding. Instead, the antibody may neutralise the virus in various other ways like creating steric hindrance (destabilisation of virus structure) or aggregation of virions.
Monoclonal antibodies are considered potent prophylactic and therapeutic agents against infectious diseases. More than 20 monoclonal antibody products are currently being used for the treatment of inflammatory diseases and cancer. Experts say that monoclonal antibodies are increasingly being considered to be therapeutic against severe viral infections.
However, studies suggest that to be effective, a group of MAbs, instead of a single antibody, needs to be used. Some of which preferably act on sites other than the receptor binding site.
The Vir study also suggested the use of a group of MAbs, and not MAb309 alone for effective viral neutralization.
The company has already teamed up with the multinational pharmaceutical firm GlaxoSmithKline to prepare two MAb309 bases products VIR-7831 and VIR-7832 to be potentially used as therapeutic agents against COVID-19 .
In the press release, Dr Herbert “Skip” Virgin, the Chief Scientific Officer at Vir said that since MAb309 is likely effective against all of the related coronavirus es and binds to a conserved site, it is unlikely that SARS-COV-2 be resistant to it.
Praising the product, Dr Phillip S. Pang, the Chief Medical Officer at Vir said that MAb309 has both potency and a high barrier to resistance, which makes it one of the best therapeutic agent against the disease.
For more information, read our article on Monoclonal antibodies and their importance in fighting COVID-19
Health articles in Firstpost are written by myUpchar.com, India’s first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.
The information provided here is intended to provide free education about certain medical conditions and certain possible treatment. It is not a substitute for examination, diagnosis, treatment, and medical care provided by a licensed and qualified health professional. If you believe you, your child or someone you know suffers from the conditions described herein, please see your health care provider immediately. Do not attempt to treat yourself, your child, or anyone else without proper medical supervision. You acknowledge and agree that neither myUpchar nor firstpost is liable for any loss or damage which may be incurred by you as a result of the information provided here, or as a result of any reliance placed by you on the completeness, accuracy or existence of any information provided herein.
COVID 19 update: Mumbai reports 31 deaths in 24 hrs, highest since October; 10,030 test positive for coronavirus
The growth rate of COVID-19 has increased to 1.79 percent, while the case doubling rate has dropped to 38 days, BMC said
The nationwide tally of COVID-19 cases rose to 1,26,86,049 while the toll increased to 1,65,547, the Union health ministry data showed
The coronavirus caseload has been on the rise in the country with more than 70,000 new infections reported in the country on Thursday.